[go: up one dir, main page]

Sugimoto et al., 2022 - Google Patents

Basics of amyloid β-protein in Alzheimer's disease

Sugimoto et al., 2022

Document ID
17694760009227039685
Author
Sugimoto A
Ono K
Publication year
Publication venue
Autophagy Dysfunction in Alzheimer's Disease and Dementia

External Links

Snippet

Amyloid β (Aβ) accumulates in the brains of patients with Alzheimer's disease. Based on the amyloid hypothesis and the oligomeric hypothesis that evolved from it, Aβ-aggregated substances are considered to be the etiology. In addition, gene mutations found in familial …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Similar Documents

Publication Publication Date Title
Estrada et al. Disrupting β-amyloid aggregation for Alzheimer disease treatment
Gallardo et al. Amyloid-β and Tau at the Crossroads of Alzheimer’s Disease
Panza et al. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
MacLeod et al. The role and therapeutic targeting of α-, β-and γ-secretase in Alzheimer's disease
Permanne et al. Reduction of amyloid load and cerebral damage in transgenic mouse model of Alzheimer's disease by treatment with a β‐sheet breaker peptide
LaFontaine et al. Amyloid-beta Alzheimer targets—protein processing, lipid rafts, and amyloid-beta pores
Bakota et al. Tau biology and tau-directed therapies for Alzheimer’s disease
Yamada et al. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs
Xilouri et al. Alpha-synuclein and protein degradation systems: a reciprocal relationship
Bell et al. Altered synaptic function in Alzheimer's disease
Filosto et al. The role of mitochondria in neurodegenerative diseases
US20100324079A1 (en) Medicament for prophylaxis and treatment of Alzheimer disease
He et al. Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease
JP2004091492A (en) Amyloid beta protein (globular assembly and use thereof)
JP2003510023A (en) Amyloid β protein (globular assembly and its use)
Chen et al. Amyloid precursor protein: a regulatory hub in Alzheimer's disease
Soto* et al. Inhibiting the conversion of soluble amyloid‐β peptide into abnormally folded amyloidogenic intermediates: relevance for Alzheimer's disease therapy
EP3638277A1 (en) Compositions and methods for beta secretase inhibition
Chen et al. Photobiomodulation modulates mitochondrial energy metabolism and ameliorates neurological damage in an APP/PS1 mousmodel of Alzheimer’s disease
US20100081613A1 (en) Methods and compositions for enhancing memory
JP2006342108A (en) Preventive and therapeutic agent for diseases caused by amylospheroids
Sugimoto et al. Basics of amyloid β-protein in Alzheimer’s disease
Chen et al. Current experimental therapy for Alzheimer's disease
JP7496997B2 (en) Modified parkin recombinant protein with improved cell permeability for the treatment of neurodegenerative diseases and its uses
Sandhya et al. Alzheimer’s disease therapeutic approaches